Clin2
NCT04014413Possibly a fitRecruiting

Fecal transplant for gut and immune-related conditions

Crohn DiseaseUlcerative ColitisCeliac DiseaseIrritable Bowel SyndromeFunctional DysphoniaConstipationClostridium Difficile InfectionDiabetes Mellitus

Treatments studied

Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Digestive system, Hormones & metabolism, Immune system & allergy, Infections, Mental health, Skin clinical trials.

This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
450 people
Ages
Any age
Study type
Interventional

Who can take part

  • You have a confirmed diagnosis of one of the listed conditions (such as Crohn’s, ulcerative colitis, celiac, IBS, or antibiotic-related diarrhea).
  • Your condition fits the trial’s planned goal (many different illnesses are allowed).
  • You do not have a known reason you cannot receive FMT through the allowed delivery methods (tube through the upper gut, or scope-based or enema methods).
  • You are not currently pregnant.
  • There is no other medical reason the study team says could make FMT unsafe or unlikely to work for you.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06071312Recruiting· Phase 1/Phase 2
Fecal transplant for C. diff and ulcerative colitis

This trial tests whether one or multiple fecal transplants from a healthy donor can help treat both a recurring C. diff infection and active ulcerative colitis. It aims to find the best schedule for the procedure.

Rome
NCT04970446Recruiting· Phase 1/Phase 2
Fecal transplant to restore gut microbes in Crohn’s

This Phase 1/2 study tests whether a fecal microbiome transplant (FMT) can reduce active inflammation in people with Crohn’s disease. It’s designed for people who currently have signs of active bowel inflammation and can attend regular procedure visits.

Melbourne, Victoria
NCT07154784Enrolling by invitation· Phase 2/Phase 3
Fecal transplant for long-term ulcerative colitis treatment

This trial tests whether fecal microbiota transplantation (FMT) can safely and effectively treat mild to moderate ulcerative colitis over the long term. FMT involves transferring stool from a healthy donor to restore a healthy balance of gut bacteria.

Seoul, Dongjak-gu
NCT05803993Recruiting
Fecal transplant to ease constipation in irritable bowel syndrome

This trial tests whether transferring stool bacteria to the gut (fecal microbiota transplantation) can reduce symptoms of irritable bowel syndrome with constipation. It may help by changing the gut microbiome, but you must meet safety and health requirements.

Roma
NCT01905709Recruiting
Fecal transplant to treat recurring C. difficile infection

This trial studies using a fecal microbiota transplant (FMT)—healthy gut bacteria moved from a screened donor—to help treat recurring or hard-to-control C. difficile infection. It may help restore a healthier gut environment when standard treatments keep failing or the infection returns.

Englewood, New Jersey
NCT05321745Recruiting
Fecal transplant for children with Crohn’s disease

This trial tests whether transferring stool microbes (called fecal microbiota transplantation, or FMT) can improve Crohn’s disease in children who have not gotten better with usual treatments. If you qualify, the study will check symptoms and colon imaging/score changes over the study follow-up.

Wuhan, Hubei

Hear when a new Ulcerative Colitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.